1. Home
  2. CISS vs AZTR Comparison

CISS vs AZTR Comparison

Compare CISS & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

HOLD

Current Price

$0.79

Market Cap

1.9M

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.16

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISS
AZTR
Founded
2022
2014
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.9M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
CISS
AZTR
Price
$0.79
$0.16
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
1.9M
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.14
52 Week High
$5.93
$1.40

Technical Indicators

Market Signals
Indicator
CISS
AZTR
Relative Strength Index (RSI) 31.83 34.97
Support Level $0.14 $0.15
Resistance Level $3.83 $0.23
Average True Range (ATR) 0.15 0.02
MACD -0.10 0.00
Stochastic Oscillator 1.05 7.29

Price Performance

Historical Comparison
CISS
AZTR

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: